i found this on reddit and am curious to know if anyone has had any good experiences repairing their brains with BPC-157:
https://www.reddit.c...as_a_nootropic/
from the link above:
BPC-157 reduces tolerance to GABAergics and possibly dopaminergics. The dosage required is much lower than current broscience would indicate.
The case for BPC-157 as a nootropicBPC-157 is an injectable peptide that doesn't get talked about around here but is well known over at /r/PEDs for it's ability to accelerate the healing of injuries. After having read through the research on pubmed and sampling it myself, I believe it deserves more attention from the Nootropics community.
Virtually all of the studies come from a group in Croatia and they always use the same doses in their mice and rat studies: 10 micrograms per kg and 10 nanograms per kg. Most of the studies find some activity at the lower dose and more activity at the higher dose. This translates to a dosage range of about 1 ng/kg to 1 mcg/kg in humans. The standard advice is to take 200 to 500 mcg for healing purposes when doses of as low as 0.1 mcg could show results.
I've been using doses in the 50-100 mcg range which is on the higher end of the experimental range for the simple reason that if I use doses lower than that the peptide will degrade before I finish it.
I'm not going to get too much into personal experience because you would expect a large placebo reaction to an injectable but it's GABAergic tolerance reducing effects are real for me. There is some evidence that it could do something similar for people who take dopaminergic drugs but I have little experience with these.
Summary of some of the more interesting researchThe antidepressant effect of an antiulcer pentadecapeptide BPC 157
- "In a forced swimming test, a reduction of the immobility time in BPC 157 ... treated rats corresponds to the activity of the ... conventional antidepressants, imipramine or nialamide"
- "In chronic unpredictable stress procedure, particular aggravation of experimental conditions markedly affected the conventional antidepressant activity, whereas BPC 157 effectiveness was continuously present."
- Reduced diazepam (valium) tolerence
- Reduced withdrawal symptoms
- Had some anticonvulsive effectiveness
- "Theoretically BPC 157 given simultaneously with repeated diazepam could act postsynaptically preventing the downregulation of the benzodiazepines receptors"
- "it could be speculated that BPC 157 acts favoring natural homeostasis of the GABA receptor complex as well as enhancing the GABAergic transmission"
- Reduced intoxication, prevented overdose death
- Reduced withdrawal symptoms
- Protected against stomach and liver lesions
BPC 157 attenuates disturbances induced by neuroleptics
- "it blocks the stereotypy produced acutely by amphetamine in rats"
- "these findings indicate that pentadecapeptide BPC 157 fully interacts with the dopamine system, both centrally and peripherally, or at least, that BPC 157 interferes with some steps involved in catalepsy and/or ulcer formation"
Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.
- "BPC 157 has a modulatory effect on dopamine system, and it could be used in chronic amphetamine disturbances"
BPC 157 effective against serotonin syndrome (2005)
- "in severe serotonin syndrome, gastric pentadecapeptide BPC 157 ... has a beneficial activity, which is likely, particular, and mostly related to a rather specific counteraction of 5-HT2A receptors phenomena"
- The down-regulation effect on the 5-HT2A receptor is interesting. From wikipedia: "findings suggest that post-synaptic 5-HT2A overdensity is involved in the pathogenesis of depression"
- Good summary of the many potential uses of BPC-157. Contains some (not properly cited) references to studies I can't find on pubmed.
- EXAMPLE 35: The Effect on Convulsions
- "KBPC157 produced a consistently positive (dose and time dependent) anti-convulsive effect against all of the applied convulsants"
- EXAMPLE 48: Effect on Cognitive Disorders
- "application of anti-cholinergic agents (scopolamine, atropine) led to a significant cognitive deficit in the rats"
- "This cognitive deficit was abolished ... by subsequent coadministration of NaBPCI 57"
- "Considering the widely implicated significance of these models for human cognitive function impairments, it is evident that NaBPCI 57 is useful in the therapy of cognitive disorders"